ADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript
FDA raised safety concerns about ZYNLONTA combination therapy in LOTIS-5 trial.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
More in Finance & Markets
THEO is Now Live on Hydrex — Autheo’s Internet Operating System Token Begins Trading
Unlike many blockchain projects that enter the public markets before meaningful adoption, THEO launches into an operational ecosystem — powering Autheo’s Intern
Pakistan expects up to $100 million under first DPR programme
In a significant development for Pakistan’s external financing landscape, a project agreement between the International Finance Corporation (IFC) and Bank Alfalah Limited (BAFL) for Pakistan’s first…
Valneva (VALN) Q2 2026 Earnings Call Transcript
Restructuring efforts and Lyme vaccine regulatory timeline take center stage.
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead
Don't bet against Vertex Pharmaceuticals in cystic fibrosis.
Inside Berkshire’s big housing market bet to buy homebuilder Taylor Morrison: ‘Blind date to the altar’
Want more housing market stories from Lance Lambert’s ResiClub in your inbox? Replacing a legendary investor like Warren Buffett—who led Berkshire Hathaway for 60 years—might be one of the toughest…
Billionaire John Malone Buys 51K Liberty Latin America Shares. What Does This Mean for Investors?
Key PointsMalone acquired 50,696 shares at a weighted-average price of $8.50 per share, representing a total capital commitment of $430,916.